Last reviewed · How we verify
NCT06932198
Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag)
Phase 1 trial testing Selexipag Film Coated Tablets in Pulmonary Arterial Hypertension (PAH) in 14 participants. Completed in 25 March 2025.
3 March 2025
Quick facts
| Lead sponsor | Humanis Saglık Anonim Sirketi |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | other |
| Enrollment | 14 |
| Start date | 9 January 2025 |
| Primary completion | 3 March 2025 |
| Estimated completion | 25 March 2025 |
| Sites | 1 location across Jordan |
Drugs / interventions tested
- Selexipag Film Coated Tablets — full drug profile →
- Uptravi® Film Coated Tablets — full drug profile →
Conditions studied
- Pulmonary Arterial Hypertension (PAH) — all drugs for Pulmonary Arterial Hypertension (PAH) →
Sponsor
Humanis Saglık Anonim Sirketi — full company profile →
Who can join
Adults 18 to 50, any sex, with Pulmonary Arterial Hypertension (PAH). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Randomized, single oral dose, two-period, two-treatment, two-sequence open-label, crossover, bioequivalence study to compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag), in healthy subjects under fed conditions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06932198
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pulmonary Arterial Hypertension (PAH)
Currently open trials in the same condition.
- NCT07245680 — COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities · Phase 3 · recruiting
- NCT06872112 — A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension · Phase 1 · recruiting
- NCT07013149 — The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension · recruiting
- NCT07457762 — AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension? · NA · recruiting
- NCT06941441 — PAH Exercise Study · Phase 3 · recruiting
Other Humanis Saglık Anonim Sirketi trials
Trials by the same sponsor.
- NCT07372118 — Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tabl · Phase 1 · completed
- NCT07278349 — Bioequivalence Study to Compare Vonoprazan 20 mg Film Coated Tablets Versus Voquezna® 20 mg (Vonoprazan) Tablets · Phase 1 · completed
- NCT07266779 — Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets and Reference Pr · Phase 1 · completed
- NCT07266766 — Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tabl · Phase 1 · completed
- NCT07266792 — Bioequivalence Study to Compare Brexpiprazole 4 mg Film Coated Tablets Versus RXULTI 4 mg Film Coated Tablet (Brexpipraz · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06932198 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Humanis Saglık Anonim Sirketi
- Last refreshed: 22 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06932198.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing